The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Celldex (Inst); EMD Serono (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer.
 
Ignacio Garrido-Laguna
No Relationships to Disclose
 
Ian E Krop
Employment - AMAG Pharmaceuticals (I)
Leadership - AMAG Pharmaceuticals (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I)
Consulting or Advisory Role - Amgen; Genentech
Research Funding - Genentech
 
Howard Burris
No Relationships to Disclose
 
Erika Paige Hamilton
Consulting or Advisory Role - Cascadian Therapeutics (Inst); Flatiron Health; Genentech/Roche (Inst); Pfizer (Inst)
Research Funding - AstraZeneca (Inst); BerGenBio (Inst); Cascadian Therapeutics (Inst); Curis (Inst); Genentech/Roche (Inst); Hutchison MediPharma (Inst); Kadmon (Inst); Lilly (Inst); Lycera (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Rgenix (Inst); Stem CentRx (Inst); Syndax (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Verastem (Inst); Zymeworks (Inst)
 
Fadi S. Braiteh
Stock and Other Ownership Interests - Agios; Bristol-Myers Squibb; Clovis Oncology; Insys Therapeutics; Tesaro
Honoraria - Abbott Nutrition; Amgen; ARIAD; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; HERON; Incyte; Insys Therapeutics; Insys Therapeutics; Ipsen; Lexicon; Lilly; Taiho Pharmaceutical
Consulting or Advisory Role - Ambry Genetics; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Incyte; Insys Therapeutics; Ipsen; Ipsen; Lexicon; Lilly; Merck; Merrimack; Pfizer; Regeneron; Sanofi
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Incyte; Insys Therapeutics; Ipsen; Lilly; Merck; Merck; Merrimack; Pfizer; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Bayer; Bayer/Onyx; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Exelixis; HERON; Incyte; Insys Therapeutics; Ipsen; Lexicon; Merrimack; Novartis; Pfizer; Regeneron; Roche/Genentech; Sanofi; Taiho Pharmaceutical; Tesaro
 
Amy Weise
No Relationships to Disclose
 
Maysa M. Abu-Khalaf
Research Funding - Clovis Oncology (Inst); Genentech/Roche (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst)
 
Christopher Zopf
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Mani Lakshminarayanan
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Jaymes S. Holland
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Raffaele Baffa
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Patents, Royalties, Other Intellectual Property - Pfizer
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Baxter; Bayer
Research Funding - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genentech; Lilly; Merck; Mirati Therapeutics; miRNA Therapeutics; Novartis; Pfizer
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
Other Relationship - Oncorena
 
Raffit Hassan
Research Funding - Aduro Biotech (Inst); Bayer (Inst); Morphotek (Inst); Roche TCRC (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for MPF assay from Morphotek (approximately $700/year)